Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

But now Pfizer hope the drug can return in a new formulation ... a filing that included new data from the phase 3 open-label study ALFA-0701 and an individual patient data meta-analysis from ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

NEW YORK, NY, USA I 13, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

For those who work from home, or spend their days behind a desk, standing desks have become popular as a way to work in less sedentary time during the day.… ...